Presented at the European Society for Medical Oncology Congress 2026 in Madrid, the randomized phase II SARON trial evaluated patients with synchronous oligometastatic non-small cell lung cancer. Researchers found that adding consolidation radiotherapy to first-line systemic anticancer therapy significantly improved progression-free survival to 13.9 months compared to 8.9 months with systemic therapy alone, though overall survival remained comparable at 31.0 and 28.0 months respectively.
For patients diagnosed with synchronous oligometastatic non-small cell lung cancer—representing an intermediate clinical state where disease spread is limited to a few specific sites—medical teams frequently debate the utility of aggressive local intervention alongside systemic therapies like chemotherapy and immunotherapy. The SARON trial, conducted between 2016 and 2023, directly tested this premise by randomizing participants into two distinct cohorts: one receiving systemic therapy alone, and another receiving targeted high-dose radiotherapy to all known sites of disease following initial systemic treatment. The trial design specifically evaluated patients without actionable genomic alterations, incorporating a mixed treatment backbone consisting of chemotherapy (40%), immunotherapy (15%), and chemoimmunotherapy (45%).
The intervention demonstrated a profound impact on local disease control. Progression at initial sites of disease dropped from 39.5% in the control group to just 13.0% in the consolidation radiotherapy arm. This divergence explains why the hazard ratio for progression-free survival reached 0.64 (95% CI 0.43–0.95; P=0.03), while the overall survival hazard ratio sat at 0.99 (95% CI 0.63–1.55; P=0.95), indicating that local eradication does not automatically neutralize occult micrometastatic disease circulating elsewhere in the body.
Targeted Radiotherapy Delays Tumor Growth Without Extending Survival
- Targeted Radiotherapy Delays Growth: High-dose radiation directed at known tumors keeps the cancer from progressing for an average of 13.9 months compared to 8.9 months with standard care alone.
- Control Versus Lifespan: While treating visible lesions dramatically reduced tumor growth at those specific sites from 39.5% down to 13%, it did not extend overall patient survival times.
- Quality of Life: The Saron trial demonstrated a significant improvement in progression-free survival without compromising quality of life.
To contextualize these findings, the SARON trial results can be evaluated alongside the foundational parameters that guided its execution. Leeds Live and Devon Live reported on the real-world impact of these findings through participants such as Julie Moran, a 69-year-old former senior cardiac technician from Buckinghamshire whose oligometastatic lung cancer was identified following a CT scan prompted by long COVID symptoms six months after contracting Covid-19 in March 2020. Moran subsequently received immunotherapy followed by targeted radiotherapy at The Royal Marsden NHS Foundation Trust, highlighting the personalized pathways enabled by multidisciplinary oncology networks.
| Trial Arm | Median Progression-Free Survival | Progression at Initial Sites | Median Overall Survival |
|---|---|---|---|
| Systemic Therapy Alone | 8.9 Months | 39.5% | 28.0 Months |
| Systemic Therapy + Radiotherapy | 13.9 Months | 13.0% | 31.0 Months |
Chief investigator Dr Fiona McDonald, a consultant thoracic clinical oncologist at The Royal Marsden NHS Foundation Trust and leader of the thoracic radiotherapy group at the Institute of Cancer Research, London, explained why this national collaboration matters during her presentation at the European Society for Medical Oncology Congress 2026. As noted by Devon Live, Dr McDonald explained that prior to these results, limited randomized evidence existed regarding the precise clinical advantages of incorporating comprehensive radiation into standard systemic regimens for oligometastatic non-small cell lung cancer.
Trial Eligibility Included Patients with Five Metastases
Patients with as many as five metastases were eligible for the trial.
Future Biomarker Integration in Oligometastatic Management
The evolution of systemic protocols throughout the enrollment window—spanning the pre-immunotherapy era into contemporary chemoimmunotherapy standards—shows that future clinical investigations need advanced predictive biomarkers. As molecular profiling, circulating tumor DNA assays, and deep radiographic response evaluations mature, clinicians will face the challenge of distinguishing between patients with truly localized metastatic potential and those harboring hidden systemic dissemination. Future prospective trials must incorporate these precision oncology tools to refine patient selection criteria, ensuring that interventions are tailored precisely to the biological signature of the malignancy rather than relying solely on lesion counts.
🫁 Better local control does not always mean longer survival.@OncoAlertAt #ESMO26, the randomized phase II SARON trial tested whether adding consolidation radiotherapy to first-line systemic therapy could improve outcomes in synchronous oligometastatic, AGA-negative #NSCLC.📊… https://t.co/svUsgxFIYE
References
- Oncodaily. SARON: Consolidation Radiotherapy Improves PFS but Not Overall Survival in Oligometastatic NSCLC.
- Leeds Live. Cancer Breakthrough Added Treatment Controls Disease for Longer.
- Devon Live. New Trial Finds Added Treatment Keeps Advanced Cancer Under Control for Longer.
More on Foundation Trust
#ESMO26 Dr. @fifimcdrmh presents the SARON trial. Phase II of consolidation radiotherapy vs systemic therapy in pts with driver negative oligometastatic NSCLC after 6-8w of control with systemic therapy. Improvement in PFS with radiation 13.9 vs 8.9m but no difference in OS. pic.twitter.com/hrnVmeH53X
OncoAlert 4Sight Abstracts to be Presented at #ESMO26Primary Results of SARON: A Randomised-Controlled Trial of Consolidation Radiotherapy for Synchronous Oligometastatic Non-Small Cell Lung Cancer @fifimcdrmh 🫁 Randomized phase II (n=140): first-line SACT ± consolidation… pic.twitter.com/Tk51vOHfsz
Keep reading
- Malieveld protesters demand research funds for post-infectious syndromes
- Makari Espe Lifted Weights 5 Days a Week for a Month: Here’s What Happened
- GDFATHER-NEO Trial Design: Neoadjuvant PD-1 Blockade With or Without Visugromab in Muscle-Invasive Bladder Cancer (world-today-news.com)
- How Congo's Ebola Trial Uses a Typhoid Shot to Test Ervebo (daybreakwire.com)
